Last reviewed · How we verify
Placebo Matched to Tocilizumab
Placebo Matched to Tocilizumab is a Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development.
This is a placebo control arm matched to tocilizumab, an IL-6 receptor antagonist, and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo Matched to Tocilizumab |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (tocilizumab) through comparison. It allows researchers to distinguish between the therapeutic effects of tocilizumab and effects due to placebo response or natural disease progression. The matched formulation ensures blinding and comparability between treatment arms.
Approved indications
Common side effects
Key clinical trials
- Tocilizumab in Lung Transplantation (PHASE2)
- Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS (PHASE3)
- An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (PHASE3)
- A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (PHASE1)
- A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Matched to Tocilizumab CI brief — competitive landscape report
- Placebo Matched to Tocilizumab updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Placebo Matched to Tocilizumab
What is Placebo Matched to Tocilizumab?
How does Placebo Matched to Tocilizumab work?
Who makes Placebo Matched to Tocilizumab?
What development phase is Placebo Matched to Tocilizumab in?
Related
- Manufacturer: Hoffmann-La Roche — full pipeline
- Compare: Placebo Matched to Tocilizumab vs similar drugs
- Pricing: Placebo Matched to Tocilizumab cost, discount & access